Panacea Biotec receives award notification from PAHO for Easyfive-TT Vaccine supply
Written By : Ruchika Sharma
Published On 2025-11-11 10:30 GMT | Update On 2025-11-11 10:30 GMT
Advertisement
New Delhi: Panacea Biotec has announced that the company has received an Award notification from Pan American Health Organization, Regional Office of World Health Organization (PAHO) under a Long-Term Agreement for supply of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine (Pentavalent) - Liquid (single dose) (“Easyfive-TT”) to PAHO, valid until December 31, 2027.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.